Submit manuscript...
Journal of
eISSN: 2373-633X

Cancer Prevention & Current Research

Research Article Volume 4 Issue 4

Contribution of Diffusion-Weighted MR Images in the Differentiation of Benign and Malign Head and Neck Mass Lesions

Senay Ertem,1 Havva Serap Toru,2 Alper Tunga Derin,3 Kamil Karaali1

1Department of Radiology, Akdeniz University, Turkey
2Department of Pathology, Akdeniz University, Turkey
3Department of Otorhinolarynglology, Akdeniz University, Turkey

Correspondence: Kamil Karaali, Department of Radiology, Akdeniz University Hospital, 07059, Antalya, Turkey, Tel 90-242-2496440

Received: February 05, 2016 | Published: March 17, 2016

Citation: Ertem Åž, Toru HS, Derin AT, Karaali K (2016) Contribution of Diffusion-Weighted MR Images in the Differentiation of Benign and Malign Head and Neck Mass Lesions. J Cancer Prev Curr Res 4(4): 00126. DOI: 10.15406/jcpcr.2016.04.00126

Download PDF

Abstract

We evaluated the value contribution of diffusion-weighted MR images in the differentiation of benign and malign neck masses. We retrospectively evaluated the findings of 102 patients with neck masses. Mean ADC (apparent diffusion coefficient) values of malignant lesions were 1,27±0,57mm2/s, 95% confidence interval was (1,18 mm2/s - 1,49 mm2/s). Mean ADC values of benign lesions were 1,61±0,67mm2/s, 95% confidence interval was (1,42 mm2/s - 1,84 mm2/s). When we compare these ADC values, mean ADC values of malignant lesions were smaller than those of benign lesions. Result was statistically significant (p<0,01). We concluded that, diffusion-weighted MR imaging may be used to help in characterization of head and neck lesions.

Keywordsmr imaging, diffusion weighted mri, neck masses

Abbreviations

MRI, magnetis resonance imaging; DWI, diffusion-weighted imaging; T, tesla; CT, computed tomography; ADC, apparent diffusion coefficient; ROC, receiver operating characteristic; ROI, region of interest

Introduction

Head and neck cancer is a significant cause of mortality worldwide. Patients treated for advanced head and neck cancer may suffer from severe sequela. Furthermore, head and neck cancer causes high health care cost. Both sequela and health care cost can be diminished with optimized treatment which requires accurate estimation of tumor size and extent. For these purpose accurate discrimination of vital tumor tissue and tumor-free soft tissue is mandatory.

CT and MRI are the two imaging modalities of choice for establishing the diagnosis and for staging head and neck cancer. But with both techniques, sometimes the discrimination of benign versus malignant tissues is difficult. The reason of this is mainly due to the fact that both of these techniques may only evaluate the macroscopic morphology of biologic tissues without reflecting the microstructural differences.

Diffusion-weighted imaging (DWI) is a non-invasive technique which analyzes the structure of a biologic tissue at a microscopic level and may therefore be a potential tool for evaluating the microstructural differences between vital tumor tissue and tumor- free tissue.

In this study our aim was to evaluate whether DWI is a feasible and reliable technique for differentiating benign from malign neoplastic tissue in the patients that reffered to our clinic and suffering from head and neck mass.

Materials and methods

We retrospectively investigated all the patients that referred to our clinic because of head and neck mass and searched for tumor recurrence or residue after chemotherapy and/or radiotherapy or surgery. For the last three years, there were 110 patients aged 0-84 years (Mean 47,5). Forty-nine of them were female, 61 were male. Eight patients were excluded because either no pathologic finding determined after routine MRI investigation or easily diagnosed by routine MRI sequences. Therefore, 102 patients were included into the study. Ethics committee approval and informed consent from all the patients were obtained.

MRI was performed using a 1,5 T MRI unit (Simens Avanto, Erlangen, Germany) and dedicated head nad neck coil was used. The Standard MRI protocol for head and neck were used. DWI always performed before application of intravenous contrast. None of the patients had major artifacts at DW imaging that warranted exclusion from the study. For quantitative analysis of tissue-spesific diffusion properties, the ADC map was created by the MRI unit automatically. ADC values were calculated offline on a pixel-by-pixel basis from user defined regions of interest (ROI). The ROI were drawn manually by two experienced radiologist after identifying the tumour on routine head and neck images. As a reference between the patients, ADC values were also measured from spinal cord or medulla oblangata. For each patient routine MR images and ADC measurements were recorded on CDs.

In 90 patients the final diagnosis were base program version 11.3.3.0) to evaluate the diagnostic capability of the ADC value for use in the differentiation between malignant and benign lesions. We made two other comparisons: First, we compared ADC values of the lesions in patients who had no prior therapy, and the patients who had chemotherapy/radiotherapy or surgery. Mann Whitney-U test SPSS program was used for the statistical analysis. Second; we compared ADC values of the lesions that are smaller and larger than 1 cm. For this comparison, we used Mann Whitney-U test SPSS program. Alpha level is accepted as 0,05.Ód on pathologic findings obtained by either biopsy or operation specimens. In 11 patients, the diagnoses were accepted as benign after 6 months of follow-up and no change was observed. In one patient, who had inoperable invasive paranasal sinus tumor (Figure 1), the diagnosis was accepted as a malign lesion. After these assesment 61 patients were diagnosed as malignant, 41 patients were diagnosed as benign. Mean ADC values of these lesions were compared statistically. The distribution of the malignant lesions is shown in Table 1. We used receiver operating characteristic (ROC) curve analysis (medcalc program version 11.3.3.0) to evaluate the diagnostic capability of the ADC value for use in the differentiation between malignant and benign lesions. We made two other comparisons: First, we compared ADC values of the lesions in patients who had no prior therapy, and the patients who had chemotherapy/radiotherapy or surgery. Mann Whitney-U test SPSS program was used for the statistical analysis. Second; we compared ADC values of the lesions that are smaller and larger than 1 cm. For this comparison, we used Mann Whitney-U test SPSS program. Alpha level is accepted as 0,05.

Figure 1 Invasive paranasal tumor. A) Precontrast T1-weighted image show mass lesion within right maxillary sinus (arrows) B) ADC measurement of the same lesion on DWI.

Squamous Cell Carcinoma

24

Nasopharyngeal Carcinoma
Nonkeratinizing Carcinoma Undifferentiated Subtype
Nonkeratinizing Carcinoma Differentiated Subtype

12

2

Malignant Epithelial Tumor

10

Leuchemia/Lymphoma

3

Salivary Gland Type
Acinic Cell Carcinoma
Adenoid Cystic Carcinoma

 

1

2

Metastatic Tumors
Embryonel Rhabdomyosarcoma
Colonic Adenocarcinoma

 

2

1

Thyroid Medullary Carcinoma
Thyroid Papillary Carcinoma

2
1

Combined Small Cell Carcinoma, Neuroendocrine Type

1

Total

61

Table 1 Distribution of malignant lesions

Results and discussion

Mean ADC values of malignant lesions were 1,27±0,57 mm2/s, 95% confidence interval was (1,18 mm2/s - 1,49 mm2/s). Mean ADC values of benign lesions were 1,61±0,67 mm2/s, 95% confidence interval was (1,42 mm2/s - 1,84 mm2/s). When we compare these ADC values, mean ADC values of malignant lesions were smaller than those of benign lesions. Result was statistically significant (p< 0,01) When the cut off value of ROC curve accepted as 1,72 the specificity was 83,6%, sensitivity was 43,9%. The area under curve was 0,660±0,0558, 95% confidence interval was 0,559 - 0,751, p value: 0,0041 positive likelihood ratio: 2,68 and negative likerlihood ratio was 0,67.

Among the malignant lesions; the smallest ADC value was measured in a case with malignant lympoma (ADC: 0,43mm2/s), the highest ADC value was measured in a patient with embryonic rhabdomyosarcoma (ADC: 2,82mm2/s).

The mean ADC value of the lesions in patients with no prior therapy ( mean: 1,14 mm2/s ; confidence interval: 0,43mm2/s - 1,89mm2/s) were smaller than those of post therapy (chemotherapy and/ or radiotherapy or surgery) group (mean: 1,37mm2/s confidence interval: 0,74 mm2/s - 3,43 mm2/s). But the result was not statistically significant (p: 0.85).

The mean ADC value of lesions larger than 1cm (mean: 1,23 mm2/s confidence interval: 0,43 mm2/s – 2,82 mm2/s) was smaller than those of lesions smaller than 1cm (mean: 1,56 mm2/s confidence interval: 0,49 mm2/s -3,43mm2/s). But the result was not statistically significant (p: 0.129).

Difusion weighted MR images are mainly used for demonstration of cytotoxic edema in early stages of brain infarction.1 However, it may also give valuable information about microstructure of tumors.2 In malign cells, nuclei are larger with high chromatine content. Tissues of malignancy also show hyper cellularity. Those micro structural characteristics result in restricted diffusion of the protons. Tumor cellularity and low ADC relationship can be demonstrated in various kinds of tumors, including head and neck tumors.3 Increased nucleocytoplasmic ratios usually result in restricted diffusion. Diffusion weighted MRI is relatively fast method and does not require contrast material injection, therefore, it can be added to routine sequences.

Friedrich et al.4 have used diffusion weighted MRI sequences with 800 s/mm2 b values and they have obtained sufficient images for the dsicrimination of tumoral and non-tumoral tissues in the head and neck squamous cell cancers4 In our study we have also used 50 and 800s/mm2 b values for diffusion weighted sequences.

Wang et al., evaluated ADC values of head and neck lesions and found that malign lesions have lower than benign lesions, also, they stated that malignant lymphomas have lower ADC values than carcinomas. As well, they found that benign cystic lesions have higher ADC values than benign solid lesions5 they found 91 % specificity and 84 % sensitivity if the cut-off value is set to 1.22x103mm2/s.

Vandecaveye et al.6 have found that malignant lyph nodes in the neck have significantly lower ADC values than benign nodes. When the cut-off value was set to 0.94x10-3mm 2/s, sensitivity was 84 % and specificity was 94 %.6 In our study, we also evaluated the lymph nodes by comparing the ADC values of those smaller and larger than 1cm but we could not find significant difference. However, the number of lymph nodes in our study was not too many and heterogeneity of the primary lesions may be the cause of non-significant results for the lymph nodes.

Maeda et al.7 have stated that DWI may be helpful in the differentiation of carcinomas and lyphomas in malignant group, and necrosis and abscess in benign group of head and neck lesions. However, they emphasized that ADC may be influenced by many factors like yumor celluratiy and matrix and ADC measurements may sometimes be confusing7 in our study, we also observed a similar overlap of the results obtained from benign and malignant group.

Razek et al.8 evaluated the masses in pediatric head and neck lesions with DWI and have found that in malignant lesions, mean ADC was 0,93x10-3mm2/s, 1,57x10-3 mm2/s in benign solid lesions and 2,01x10-3 mm2/s in benign cystic lesions. The difference was significant between benign and malignant group.8

Tumor necrosis and cystic degeneration may decrease the restricted diffusion of malignant masses. It is recommended that, ADC measurement should be performed from enhancing solid portions of tumors.8 However, very small necrosis areas may also be present and result in higher ADC values of malignant masses. Sumi et al.9 have found that metastatic lymoh nodes have higher ADC values than benign lymph nodes. This was explained by the presence of necrosis within the lymph nodes9 In our study, highest ADC value observed in malign masses was 2.82mm2/s in a embryonal rhabdomyosarcoma metastasis and we thought that this was due to intrinsic necrosis (Figure 2).

Figure 2 Metastasis of embryonal rhabdomyosarcoma. (A and B) Coronal and axial T2-weighted fat-suppressed images show necrotic lymph node (arrows). (C) ADC measurement of the same lesion on DWI.

Conclusion

In conclusion, diffusion-weighted MR imaging may be used to help in characterization of head and neck lesions. Since the DW MRI sequence is fast and effective, it should be a part of routine head and neck imaging protocol in clinical practice. However, it should be kept in mind that measureöents should be made from the solid portions of the lesions. As well, overlapping results may still be observed and DWI should only be used as additional information to conventional sectional images.

Funding

None.

Acknowledgments

None.

Conflicts of interest

The authors declare no conflict of interest.

References

  1. Minaei A, Sabzichi M, Ramezani F, et al. Co–delivery with nano–quercetin enhances doxorubicin–mediated cytotoxicity against MCF–7 cells. Molecular Biology Reports. 2016;43(2):99–105.
  2. Akter R, Hossain MZ, Kleve MG, et al. Wortmannin induces MCF–7 breast cancer cell death via the apoptotic pathway, involving chromatin condensation, generation of reactive oxygen species, and membrane blebbing. Breast Cancer (Dove Med Press). 2012;4: 103 –113.
  3. Ahmad S, Singh N, Glazer RI. Role of AKT1 in 17 beta–estradiol–and insulin–like growth factor I (IGF–I) – dependent proliferation and prevention of apoptosis in MCF–7 breast carcinoma cells. Biochemistry Pharmacology. 1999;58(3):425–430.
  4. Jia T, Zhang L, Duan Y, Zhang M, et al. The differential susceptibilities of MCF–7 and MDA–MB–231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt–SKP2–Cip/Kips pathway. Cancer Cell Int. 2014;14(1):126.  
  5. Knuefermann C, Lu Y, Liu B. HER2/PI–3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22(21):3205–3012.
  6. Karve S, Werner ME, Sukumar R, et al. Revival of the abandoned therapeutic Wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci USA. 2012;109(21):8230–8235.
  7. Hossain M Z, Kleve MG. Nickel nanowires induced and reactive oxygen species mediated apoptosis in human pancreatic adenocarcinoma cells. Int J Nanomedicine. 2011;6:1475–1485.
  8. Syamsudin P, Simanjuntak R, Djamil, et al. Apoptosis of Human Breast Cancer Cells induced by Ethylacetate Extracts of Propolis. Am J Biochem Biotechnol. 2010;6(2):84–88.
  9. Belyaeva EA, Dymkowska D, Wieckowski MR, et al. Reactive oxygen species produced by the mitochondrial respiratory chain are involved in Cd2+–induced injury of rat ascites hepatoma AS–30D cells. Biochim Biophys Acta. 2006;1757(12):1568–1574.
  10. Mousavi SH, Najaran TZ, Hersey P. Apoptosis: from Signalling Pathways to Therapeutic Tools. Iran. J Basic Med Sci 2008;11(3):121–142.
  11. Potten C, Wilson J. Apoptosis: The Life and Death of Cells. Cambridge University Press, USA. 2005.
  12.  Yang HL, Chen CS, Chang WH, et al. (2006) Growth inhibition and induction of apoptosis in MCF–7 breast cancer cells by Antrodia camphorate. Cancer Letters. 2006;231(2):215–227.
  13. Merlin NJ, Parthasarathy V, Santhoshkumar TR. Induction of apoptosis in human breast cancer cell line MCF–7 by phytochemicals from Gmelina asiatica. African Journal of Biotechnology. 2010;9(28):4451–4456.
  14. Zhang Y, Cai X, Wang Y, et al. Non–Invasive Photoacoustic Microscopy of Living Cells in Two and Three Dimensions through Enhancement by a Metabolite Dye. Angewandte Chemie (International Edition). 2011;50(32):7359–7363.
  15.  Mosmann TR Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
  16. Sobhani Z, Dinarvand R, Atyabi F, et al. Increased paclitaxel cytotoxicity against cancer cell lines using a novel functionalized carbon nanotube. Int J Nanomedicine. 2011;6:705–719.
  17.  Sun C, Zhang M, Shan X, Zhou X, et al. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol. 2010;136(4):603–610.
  18. Wymann MP, Bulgarelli–Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3–kinase by covalent modification of Lys–802, a residue involved in the phosphate transfer reaction. Mol Cell Biol. 1996;16(4):1722–1733.
  19. Schultz RM, Merriman RL, Andis SL, et al. In vitro and in vivo antitumor activity of the phosphatidylinositol–3–kinase inhibitor, Wortmannin. Anticancer Res. 1995;15(4):1135–1139.
  20. Davol PA, Bizuneh A, Frackelton AR. Wortmannin, a phosphoinositide 3kinase inhibitor, selectively enhances cytotoxicity of receptor–directed–toxin chimeras in vitro and in vivo. Anticancer Res. 1999;19(3A):1705–1713.
  21. Price BD, Price BD, Youmell MB. The phosphatidylinositol 3–kinase inhibitor Wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 1996;56(2):246–250.  
  22. Lemke LE, Paine–Murrieta GD, Taylor CW. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel Wortmannin–insensitive phosphatidylinositol–3–kinase. Cancer Chemo ther Pharmacol. 1999;44(6):491–497.
  23. Shim HY, Park JH, Paik HD, et al. Acacetin–induced apoptosis of human breast cancer MCF–7 cells involves caspase cascade, mitochondria mediated death signaling and SAPK/JNK1/2–c–Jun activation. Mol Cells. 2007;24(1):95–104.
  24. Zhang XD, Susan K, Gillespie SK, et al. Staurosporine induces apoptosis of melanoma by both caspase–dependent and –independent apoptotic pathways. Mol Cancer Ther. 2005;3:187.
  25. Song MM, Song WJ, Bi H, et al. Cytotoxicity and cellular uptake of iron nanowires. Biomaterials. 2010;31(7):1509–1517.
Creative Commons Attribution License

©2016 Ertem, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.

Citations